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Splice Mutation in the Iron-Sulfur Cluster Scaffold
Protein ISCU Causes Myopathy with Exercise Intolerance
Fanny Mochel,1,10,* Melanie A. Knight,2,10 Wing-Hang Tong,3 Dena Hernandez,4 Karen Ayyad,5
Tanja Taivassalo,6 Peter M. Andersen,7 Andrew Singleton,4 Tracey A. Rouault,3 Kenneth H. Fischbeck,2
and Ronald G. Haller5,8,9
A myopathy with severe exercise intolerance and myoglobinuria has been described in patients from northern Sweden, with associated
deﬁciencies of succinate dehydrogenase and aconitase in skeletal muscle. We identiﬁed the gene for the iron-sulfur cluster scaffold pro-
tein ISCU as a candidate within a region of shared homozygosity among patients with this disease. We found a single mutation in ISCU
that likely strengthens a weak splice acceptor site, with consequent exon retention. A marked reduction of ISCU mRNA and mitochon-
drial ISCU protein in patient muscle was associated with a decrease in the iron regulatory protein IRP1 and intracellular iron overload in
skeletal muscle, consistent with a muscle-speciﬁc alteration of iron homeostasis in this disease. ISCU interacts with the Friedreich ataxia
gene product frataxin in iron-sulfur cluster biosynthesis. Our results therefore extend the range of known human diseases that are caused
by defects in iron-sulfur cluster biogenesis.Introduction
Myopathy with deﬁciency of succinate dehydrogenase and
aconitase was initially reported by Larsson et al. in 14
patients from ﬁve families in northern Sweden.1–3 The dis-
ease is characterized by lifelong severe exercise intolerance,
in which minor exertion causes fatigue of active muscles,
shortness of breath, and cardiac palpitations in association
with lactic acidosis. Patients also experience episodes of
rhabdomyolysis associated with muscle swelling and
pain, weakness that may be profound, and myoglobinuria.
Physiological investigations of these patients during exer-
cise showed impaired muscle oxidative phosphorylation.
Low maximal muscle oxygen extraction was associated
with exaggerated circulatory responses, where the increase
in cardiac output relative to oxygen utilization during
exercise was four to six times normal. Biochemical studies
indicated a deﬁciency in succinate dehydrogenase (SDH)4
and aconitase5 activities and the presence of electron-
dense, iron-rich mitochondrial inclusions.5 A more gener-
alized abnormality of muscle mitochondrial iron-sulfur-
cluster-containing proteins, including the mature Rieske
iron-sulfur protein of complex III and several subunits of
complex I, was subsequently demonstrated,6 with the
heart and vascular smooth muscles spared. In the current
study, we found a common region of homozygosity in
three patients from three families originating from north-
ern Sweden and conﬁrmed a founder haplotype. Within
that interval, we further identiﬁed a single intronic muta-
tion in the gene for the iron-sulfur cluster scaffold protein
ISCU. This homozygous mutation strengthens a weaksplice acceptor site and results in reduced levels of ISCU
mRNA and protein, leading to adverse effects on iron-
sulfur proteins and intracellular iron homeostasis.
Material and Methods
Affected Individuals and Families
We studied three affected individuals (P1, P2, and P3), aged 37, 39,
and 66 years, respectively, from three different pedigrees and the
unaffected offspring (H1), aged 44 years, of one of the affected in-
dividuals (P3). There was no known consanguinity in any of the
three families, all of which originated in northern Sweden. Patient
P1 has been extensively reported elsewhere,5,6 and patient P3
belongs to family A in the genealogical report of Drugge et al.3
All patients had a history of lifelong exercise intolerance with
symptoms of muscle fatigue, shortness of breath, and tachycardia
with minor levels of physical exertion, associated with episodes of
myoglobinuria. Physiological investigations revealed low work
(0.3–0.5 W/kg, normal mean 2–3 W/kg) and oxidative capacity
(10 to 12 ml/kg/min, normal mean 5 standard deviation [SD],
39 5 5 ml/kg/min) in all patients, together with a marked deﬁ-
ciency of succinate dehydrogenase (SDH, 0.5 to 0.8 mmol/min
per g tissue, normal mean5 SD 1.85 0.5 mmol/min per g tissue)
and aconitase (1.9 to 3.1 mmol/min per g tissue, normal mean 5
SD 7.8 5 2.0 mmol/min per g tissue) in the patients’ muscle. The
unaffected offspring, H1, had normal results of both physiological
and biochemical investigations. We obtained blood samples and
skin and muscle biopsies from the three affected individuals and
the unaffected offspring after they had given written consent in
accordance with the Institutional Review Board for Human Studies
of the University of Texas, Southwestern Medical School, which
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from leukocytes via standard procedures. Skin biopsy was per-
formed on the volar forearm with a 4 mm diameter skin-biopsy
punch (Miltex), and ﬁbroblasts were cultured in fetal calf serum.
Vastus lateralis muscle biopsies were performed with a 6G Berg-
strom needle (Popper). Muscle samples were snap frozen and
stored in liquid nitrogen until analyzed biochemically, or they
were frozen in 2-methylbutane (isopentane), precooled to approx-
imately150C in liquid nitrogen, and then stored at80C or in
liquid nitrogen for histochemistry.
SNP Microarray Genotyping and Mutation Detection
The disease was assumed to be recessive with homozygosity by
descent. The four individuals were genotyped with Inﬁnium
HumanHap550 SNP genotyping chips, which contain 555,352
unique SNPs, as per the manufacturer’s instructions (Illumina).
An Illumina BeadStation scanner and data-collection software
were used to collect the data. BeadStudio’s genotyping module
(v2.3.25, Illumina) was used to generate genotypes. Genome
viewer, a visualization tool from BeadStudio, was then used to in-
vestigate the log R ratio and the B allele frequencies of the SNPs.
Thecandidategene ISCUwasPCRampliﬁedandsequenced in the
four genomic DNA samples by dye-terminator sequencing (BigDye
version3.1;AppliedBiosystems). For the ISCUgenomicDNAampli-
ﬁcation, primer setswere designed to cover the entire sequence and
2 kb upstream of the ISCU gene (primer sequences and conditions
used in the sequencing analysis are available upon request). Se-
quences were aligned and compared with consensus database se-
quences with Sequencher 4.7 software (Gene Codes Corporation).
RNA Analysis
RNA was extracted from muscle of the three affected and unaf-
fected individuals and two unrelated controls. Total RNA was
Table 1. Quantitative RT-PCR Primer and Probe Sequences Used to Amplify and Quantitate the ISCU Transcripts
ISCU Exon Forward Primer (50–30) Reverse Primer (50–30) Probe
1A/2 CCCCGGCCCGACTCTAT CAGTCCAGTTCCAACATTTTTAGATG AAGGTTGTTGATCATTATGAAAATCCTAGAAACG
1A/1B CCCCGGCCCGACTCTA TTTTGTGTCTCCTCTACAATACTTCACA CACAAGAAGGTATCTCAAA
2/3 GTGGTGACGTAATGAAATTACAGATTC TAATGAGCTGGAGGCAATTGC TGGATGCTAGGTTTAAAACATTTGGCTGTGGTT
3/4 CCACTGAATGGGTGAAAGGAA GCAGAGCTCCTTGGCGATAT CGGTGGAGGAAGCCTTGACTATCAAAAACA
4/5 TGCCTTCCTCCCGTGAAAC CCAGGGCGGCCTTGA ACTGCTCCATGCTGGCTGAAGATGC
Figure 1. Homozygosity Mapping by SNP Microarray in the Swedish Families
Homozygosity mapping by SNP array in the three northern Swedish families with myopathy and deficiency of succinate dehydrogenase
and aconitase. Each panel shows results from the affected individuals (patients P1 to P3) and the unaffected family member (individual
H1). The horizontal band in each panel represents heterozygous signal from two-allele SNP markers distributed along chromosome 12. The
gray shaded box indicates a region of homozygosity (loss of heterozygous signal) at 12q shared by all three affected individuals and not
the unaffected son H1 of affected individual P3.
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Figure 2. SNP-Array Genotyping and Mutation Detection in the Swedish Families
Pedigrees and electropherograms of the ISCU mutation (g.7044 G/C) in the three families from northern Sweden, and SNP alleles flank-
ing the ISCU gene. The positions of the SNP markers on chromosome 12 are indicated in Mb, with the corresponding alleles designated by
A and B. AA or BB indicates that the proband is homozygous for SNP markers that surround the ISCU gene (the position is shown by an
arrow). Double-headed arrows indicate a long stretch of homozygous markers. All patients share the same homozygous haplotype
(highlighted in blue), consistent with a common origin.isolated from 50 mg of muscle tissue with the QIAGEN RNeasy Fi-
brous Tissue Kit as per the manufacturer’s instructions. Fibroblasts
from two affected homozygotes, the heterozygote, and a control
were maintained in Dulbecco’s modiﬁed Eagle’s medium
(DMEM) containing 20% fetal bovine serum, 2 mM L-glutamine,
and antibiotics. The cells were then harvested for RNA and protein
isolation and quantiﬁcation. TRIzol reagent (Invitrogen) was used
to isolate total RNA from the ﬁbroblasts, and the RNeasy Mini kit
(QIAGEN) was used to purify the RNA. The total RNA frommuscle
and ﬁbroblasts was then converted to cDNA by the High Capacity
cDNA Reverse Transcription Kit (Applied Biosystems). Speciﬁc
primers and probes (Table 1) were designed with the Primer
Express Program (Applied Biosystems) and used to amplify the
ISCU mRNA. Primers to amplify the internal control human
beta-glucuronidase (HGUSB) were purchased from Applied Biosys-
tems. Quantitative reverse transcriptase PCR (RT-PCR) reactions
were run in triplicate, and the experiments were performed in trip-
licate with the ABI Prism 7900 Sequence Detector System (Applied654 The American Journal of Human Genetics 82, 652–660, MarchBiosystems). The PCR cycling conditions were standard 95C for
10 min for one cycle, 95C for 15 s, and 60C for 1 min for 40
cycles. The level of each transcript was quantiﬁed by the cycle at
which the PCR ampliﬁcation was in log phase where there was sig-
niﬁcant ﬂuorescent signal (Ct) with HGUSB as the endogenous
control. The values were normalized to the mean of the unrelated
controls via the 2-DDCt method. RT-PCR reactions were used to an-
alyze possible splice variants. The following ISCU-speciﬁc primers
were used: 50-GATATCGCCAAGGAGCTCTG-30 (RT-PCR 5-5.2F,
Exon 4) and the antisense primers 50-GACCAAACTGGAAAGCC
AAG-30 (RT-PCR 5-5.2R, Exon 4A) and 50-TCATTTCTTCTCT
GCCTCTCC-30 (WHT 20 R, Exon 5). Each RT-PCR reaction was
done in a total reaction volume of 15 ml containing the following:
12 ml of FastStart PCR Master Mix (Roche Applied Science), 1 ml of
each primer (10 pmol/ml), and 1 ml of cDNA solution. The cycling
parameters were as follows: 95C for 10 min to denature the DNA;
10 cycles of 95C for 30 s, 60C for 30 s, and 72C for 30 s; 20
cycles of 95C for 30 s, 55C for 30 s, and 72C for 30 s; and2008
then one cycle of 72C for 10 min. The RT-PCR reactions were
analyzed on a 2% agarose gel to characterize alternate splicing.
Aconitase Activity and Western Blotting
Muscle lysates were prepared in an anaerobic chamber to mini-
mize loss of enzyme activity and degradation of oxygen-sensitive
proteins. Frozen muscle samples were homogenized with a mortar
and pestle chilled with liquid nitrogen andwere lysed in argon-sat-
urated lysis buffer containing 25 mM Tris-Cl (pH 7.5), 40 mM KCl,
1% Triton, 2 mM citrate, 1 mMDTT, 0.6 mMMnCl2, 1 mMAEBSF,
and complete TM EDTA-free protease inhibitor cocktail (Roche Ap-
plied Science). The mitochondrial and cytosolic aconitases were
separated from total cellular extracts electrophoretically on non-
denaturing PAGE, and the aconitase activity was performed as
previously described.7 The antibodies used in these studies were
as follows: rabbit polyclonal anti-IRP1,7 rabbit polyclonal anti-
m-aconitase,7 and monoclonal anti-tubulin (Sigma). For ISCU,
we used rabbit polyclonal antibody,8 for which the epitope is in
the middle of the protein (KLQIQVDEKGKIVDARFK) and mostly
encoded by exon 3.
Histochemistry Studies
Unﬁxed frozen muscle sections were serially cut at 10 mm thick-
ness, applied to cover glasses or glass-plus slides, and air-dried.
SDH stains were performed immediately after sectioning as previ-
ously described.9 Serial sections reserved for iron staining were
Figure 3. Sequences of the Splice
Mutation and the Additional Exon 4A
The intronic Swedish myopathy mutation,
and exon 4A. Genomic sequences of exons
4 and 5 with the corresponding protein
residues indicated in purple. The intronic
mutation in patients (g.7044 G/C), indi-
cated by an arrow, extends a polypyrimi-
dine tract (in green) and leads to the inclu-
sion of an additional exon 4A (in blue) that
is predicted to result in a premature stop
codon (marked as *) 53 bp upstream from
the last exon junction. Numbers indicate
ISCU protein-codon residues.
wrapped in foil and stored at 80C. Sec-
tions were thawed just prior to staining.
Perl’s Prussian Blue stain for ferric iron
was adapted from a protocol previously de-
scribed.7 Muscle sections were ﬁxed in
10% neutral buffered formalin solution
for 10 min, followed by rinsing in Milli-
pore Milli-Q Plus water for 5 min. Sections
were then incubated at room temperature
in Perl’s solution (freshly made aqueous
solution of 2% potassium ferrocyanide
and 2% HCl). Sections were then rinsed
in Millipore Milli-Q Plus running water
for 5 min, followed by incubation in DAB
Stain (1.0 M Tris-HCl buffer, pH 7.5 [40
ml], with 3% H202 [1 ml] and 30 mg
DAB) for 30 min at room temperature.
Slides were rinsed in running tap water
for 5 min. They were then dehydrated in alcohol (95% 3 2;
100% 3 3), cleared in xylenes (3 3), and mounted with Cytoseal
mounting medium. Photomicrographic images were observed
with a Nikon FXA Microphot and were captured with a Nikon
DXM 1200F camera.
Results
Weused single-nucleotide polymorphism (SNP)microarray
genotyping for homozygosity mapping in three affected
patients and one patient’s unaffected offspring in three sep-
arate families from northern Sweden. The SNP analysis
showed shared homozygosity in the affected individuals
in a 2.7 Mb segment of chromosome 12q (Figure 1). Haplo-
types were conserved across the interval of homozygosity,
consistent with a common origin (Figure 1). This interval
contains 43 known genes and two open reading frames,
among which the iron-sulfur-cluster assembly enzyme
ISCUwas themost likely candidate in light of the biochem-
ical defect in the patient muscle. ISCU is believed to be the
primary scaffold uponwhich iron-sulfur clusters are assem-
bled, and it has two known isoforms in humans, cytosolic
and mitochondrial, resulting from alternative splicing
near the 50 end of the pre-mRNA.8,10 These isoforms are
thought to coordinately drive the reprogramming of iron
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Figure 4. Abnormal ISCU Transcripts
and Predicted Alteration of the Peptide
Sequence
(A) RT-PCR between exons 4 and 5, show-
ing two different transcripts in patients
and controls, the normal transcript con-
taining exons 4 and 5, and one containing
exons 4, 4A, and 5, as confirmed by cDNA
sequencing. The retention of exon 4A is
markedly enhanced in patient muscle.
Both transcripts are present in the hetero-
zygote. Note the presence of an additional
larger transcript in patient muscle (gray
arrowhead), for which cDNA sequencing re-
vealed the presence of exons 4, 4A, and 5,
as well as the retention of the intronic se-
quence between exon 4A and exon 5. These
transcripts are in very low abundance, and
their rare presence in control muscle as
well (data not shown) strongly argues
against their having a role in the disease.
L indicates cDNA from lymphoblastoid cells
from controls; P, H, and C indicate cDNA
from muscle of the three northern Swedish
patients, the heterozygote, and controls,
respectively; M indicates 100 bp DNA
ladder (Invitrogen); and * indicates no
cDNA control.
(B) Alignment of residues encoded by
exons 4 and 5, showing the strong conser-
vation of ISCU among species, as well as the alteration of the C terminus of ISCU resulting from the splice mutation in patients (SM).
Numbers designate ISCU protein-codon residues, and the residues corresponding to the a6-helix are indicated.metabolism in different subcellular compartments to regu-
late overall cellular iron trafﬁcking in response to iron
needs.7 We sequenced all exons and introns, the 30UTR,
and 2 kb upstream of the ISCU gene to cover the likely
promoter region. We found a single intronic change at po-
sition 107,485,556 bp of chromosome 12, hereafter named
g.7044 G/C (GenBank accession number EU334585),
homozygous in all patients and heterozygous in the unaf-
fected offspring (Figure 2). We analyzed 568 chromosomes
from controls originating from the same region in northern
Sweden as the patients and found only three heterozygous
changes of this nucleotide, resulting in an allele frequency
of approximately 1/188 in this population. We also ana-
lyzed 584 chromosomes from non-Swedish European and
American controls and found no change of this nucleotide.
Because this mutation replaces a repressive G with a C
and extends an intronic polypyrimidine tract in intron 4
(to TCTTTC instead of TCTTTG),11 we hypothesized that
it induced abnormal splicing of the ISCU pre-mRNAs.
The splice prediction tool of Berkeley Drosophila Genome
Project conﬁrmed that the genomic position at which we
found the homozygous change is located within the poly-
pyrimidine tract of a potential splice acceptor site, which
would promote spliceosome assembly. The probability
score for this splice acceptor site to be functional would
be strengthened from 0.87 (on a scale from 0 to 1) to
0.95, as a result of the single-nucleotide substitution found656 The American Journal of Human Genetics 82, 652–660, Marchin the Swedish patients. Similar results were obtained
when other splice prediction tools were used, e.g., Net-
Gene2 server. RT-PCR performed in patient and control
muscle with subsequent cDNA sequencing revealed the
existence of a previously unrecognized ISCU transcript
containing an additional exon (exon 4A, GenBank acces-
sion number EU329002), upstream of the known terminal
exon (Figures 3 and 4A). Quantitative RT-PCR performed in
patient muscle conﬁrmed that the retention of exon 4A in
the ISCU mRNA is markedly enhanced compared to con-
trols (data not shown). With the homozygous mutation,
the ISCU transcripts containing exon 4A are more abun-
dant in patient muscle compared to controls (Figure 4A).
In addition, qRT-PCR revealed a decrease in the total
ISCU mRNA levels in patient muscle; exon 1A-2, 1A-1B,
2-3, and 3-4 levels were 38%–46%, 18%–44%, 40%–46%,
and 35%–43% of controls, respectively, whereas exon 4-5
levels were 7%–8% of controls. It is possible that the stabil-
ity of the ISCU mRNA is altered in skeletal muscle because
of the inclusion of the Swedish myopathy exon, which
would introduce a premature stop codon 53 bp upstream
from the last exon junction and therefore possibly activate
nonsense-mediated decay (NMD) (Figure 3). However, we
could not test this hypothesis because the level of ISCU
mRNA in cultured ﬁbroblasts was normal. Accordingly,
when we added cycloheximide, mRNA levels from patient
ﬁbroblasts did not change. Use of cycloheximide in2008
cultured muscle cells from patients could potentially allow
insight into whymRNA levels decrease in the skeletal mus-
cle of these patients, where NMD may be selectively
activated.12 Further studies in patient muscle indicate the
existence of additional transcripts also containing se-
quences of the exon 4A (Figure 4A). However, these tran-
scripts are in very low abundance, and their rare presence
in control muscle as well (data not shown) strongly argues
against their having a role in the disease.
Consistent with a deleterious effect of the mutation on
the ISCU protein, western-blot analysis of patient muscle
showed a substantial reduction of the normal mitochon-
drial isoform (m-ISCU) (Figure 4A), in agreement with the
major reduction of normal transcript containing exons 4
and 5 in patient muscle (to 7%–8% compared of controls).
Furthermore, themutation is predicted to alter the C termi-
nus of ISCU, especially the highly conserved residues that
are within the sixth a-helix (Figure 4B). Because this struc-
tural alteration is in the proximity of one of the invariant
cysteine residues that are involved in the coordination of
the iron-sulfur cluster,13 it would probably diminish the
ability of the mutant protein to assemble and deliver iron-
sulfur cluster to target proteins. Given that the epitope for
Figure 5. Mitochondrial ISCU and Iron-Sulfur-Cluster-
Containing Proteins in Skeletal Muscle
Mitochondrial ISCU (m-ISCU) and iron-sulfur-cluster-contain-
ing proteins in muscle from northern Swedish patients (P1–
P3), the unaffected offspring (H1), controls (C), and a patient
with a myopathy due to a mitochondrial DNA deletion (M).
(A) Western blots of m-ISCU and mitochondrial aconitase show a
marked reduction in patient muscle. Note the increased m-ISCU
level in the control patient with mitochondrial myopathy.
(B) Aconitase enzymatic activity was determined after separa-
tion of cellular extracts in nondenaturing PAGE. The fast band
corresponds to cytosolic aconitase (c-aconitase), and the
slower band corresponds to the mitochondrial isoform (m-aco-
nitase). The activities of both c- and m-aconitase are deficient
in patients. Western blots of the iron-regulatory protein IRP1
also show reduced protein levels in patient muscle, consistent
with the decrease in c-aconitase activity.
(C) Activation of IRP1 to iron-responsive elements (IREs) with
b-mercaptoethanol in skeletal muscles from northern Swedish
patients (P1–P3), the unaffected offspring (H1), and controls
(C). b-mercaptoethanol activates the binding of IRP1 to tran-
scripts containing IRE by converting cytosolic aconitase to
the IRE-binding form. There is no activation of IRE-binding in
patients in contrast to controls, consistent with the decrease
in aconitase activity in the patient samples.
the ISCU antibody recognizes a part of the protein that
ismostly encodedby exon3, bothwild-type andmutant
proteins would be recognized. However, the western
blot did not detect anymutantm-ISCU. Thismay be ex-
plained by the following: (1) the activation of NMD in
patient muscle as a result of the premature stop codon
and consistent with the overall reduction of ISCU tran-
scripts (40% of controls on average); (2) the splicing de-
fect resulting in an alteration of the C terminus of ISCU,
a change that could affect the stability of mutant peptide
or its ability todimerizeproperly;14 and (3) adominant-neg-
ative effect of themutant peptide on the stability and func-
tioning of the normal peptide.
We analyzed the functional consequences of low muscle
m-ISCU on iron-sulfur proteins and intracellular iron ho-
meostasis in patient muscle. Activities of both mitochon-
drial aconitase and the bifunctional cytosolic aconitase/
iron regulatory protein 1 (IRP1)15 were decreased in the
patient muscle (Figure 5B). Supporting previous biochem-
ical ﬁndings, the protein levels of mitochondrial aconitase
were reduced in patients compared to controls (Figure 5A).
The protein levels of the iron-sensing protein IRP1 were
also low in patient muscle (Figure 5B), suggesting a destabi-
lization of these iron-sulfur proteins as a result of the loss
of iron-sulfur clusters.16 Addition of a reductant such as
b-mercaptoethanol activates the binding of IRP1 to tran-
scripts containing iron-responsive elements (IREs) by con-
verting cytosolic aconitase to the IRE-binding form. Gel-
shift assays showed that the amount of activatable IRP1
was reduced in patients compared to controls, consistent
with the decrease in aconitase activity (Figure 5C). InThe American Journal of Human Genetics 82, 652–660, March 2008 657
addition, histochemical studies showed a notable increase
in iron staining in patient muscle ﬁbers compared to con-
trols (Figure 6). This iron overload was observed exclu-
sively in SDH-negative ﬁbers, where m-ISCU is likely to
be most depleted (Figures 6A and 6B). However, we found
no evidence of ﬁber-type speciﬁcity with respect to SDH-
negative, iron-overloaded ﬁbers. The punctate distribution
of the iron staining in patients with this myopathy with
deﬁciency of succinate dehydrogenase and aconitase is
consistent with the mitochondrial iron overload previ-
ously detected in ultrastructural studies of these patients.5
This punctate ferric-iron staining is also reminiscent of
the iron deposition pattern observed in cells depleted of
m-ISCU by siRNA silencing,7 emphasizing the down-
stream effect of the splice mutation on mitochondrial
iron homeostasis in the muscle of these patients. Interest-
ingly, all biochemical and histological studies were nor-
mal in the heterozygous individual (Figures 5 and 6), con-
sistent with a gene-dosage effect in this disease. To
conﬁrm that deﬁciency of m-ISCU is not a nonspeciﬁc ef-
fect of mitochondrial respiratory-chain defects, we ana-
lyzed muscle from a patient with a mitochondrial myop-
athy due to a single large mitochondrial DNA deletion,
Figure 6. SDH and Iron Staining in
Skeletal Muscle
Histochemistry of skeletal muscle from
a northern Swedish patient (A and B), the
heterozygote (C and D), and a control (E
and F). Serial sections were stained for fer-
ric iron (A, C, and E) and SDH (B, D, and F).
Note the presence of intracellular iron
overload in SDH-deficient fibers (marked
with *) in the patient sample. The punc-
tate distribution of the iron staining is
consistent with the mitochondrial iron
overload previously detected in ultrastruc-
tural studies of these patients.5
which was abundant in the skeletal
muscle. This patient’s muscle had
normal aconitase activity (Figure 5B)
and normal SDH and iron staining
(data not shown), as well as a relative
increase (rather than a decrease) in
m-ISCU levels (Figure 5A).
Discussion
We have shown that myopathy with
deﬁciency of succinate dehydroge-
nase and aconitase is an autosomal-
recessive metabolic disease caused by
mutations in the ISCU gene. The
splice mutation detected in patients
from northern Sweden results in aber-
rant splicing, with the increased re-
tention of an additional exon and the introduction of a pre-
mature stop codon in the penultimate exon; this
ultimately alters the C terminus of the protein and de-
creases levels of ISCU mRNA and protein. The depletion
of mitochondrial ISCU in muscle accounts for the bio-
chemical and clinical phenotype, which is characterized
by a deﬁciency in mitochondrial iron-sulfur proteins and
impaired muscle oxidative metabolism.
Iron-sulfur clusters are prosthetic groups composed of
iron and sulfur and are usually ligated to proteins via the
sulfhydryl side chains of cysteine. Iron-sulfur clusters often
function as electron acceptors or donors, and they are im-
portant for function of the mitochondrial respiratory
chain. In humans, there are twelve known iron-sulfur clus-
ters in respiratory complexes I–III. In addition to their im-
portance in electron transfer, iron-sulfur clusters can ligate
substrate in enzymes such as aconitase, which converts cit-
rate to isocitrate, and iron-sulfur proteins can also have im-
portant structural and sensing roles.10 In mammalian iron-
sulfur-cluster assembly, a cysteine desulfurase known as
ISCS provides sulfur, and assembly of nascent iron-sulfur
clusters takes place on ISCU, which functions as a scaffold
upon which the cluster is assembled.17 Frataxin is thought
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to participate in iron-sulfur-cluster assembly by binding
ferrous iron to acidic residues18 and thereby maintaining
iron in a nonaggregated bioavailable form. In addition,
frataxin physically interacts with ISCU, and this interac-
tion probably facilitates delivery of iron from frataxin to
nascent iron-sulfur clusters on ISCU.19
The loss of the mitochondrial protein frataxin in Frie-
dreich’s ataxia is associated with reduced activity of various
mitochondrial iron-sulfur proteins, including aconi-
tase,20,21 and loss of frataxin eventually causes mitochon-
drial iron accumulation in the central nervous system and
heart.10,20 Also, loss of glutaredoxin 5, which is important
in iron-sulfur-cluster assembly,22 results in sideroblastic
anemia in humans with a glutaredoxin 5 splicing defect.23
Of note, the deﬁning characteristic of sideroblastic anemias
is mitochondrial iron overload. Similarly, ISCU depletion
results in abnormal iron staining, both in the muscle of
patients with this myopathy5 (Figure 6) and in cell culture
when ISCU levels are reduced by RNAi techniques.7 Swed-
ish myopathy therefore represents another example in
which decreased ability to synthesize iron-sulfur clusters
leads tomitochondrial iron overload. This observation sup-
ports the possibility that one or more iron-sulfur-cluster
proteins act as sensors for regulation of mitochondrial
iron homeostasis.10 ISCU is now the third iron-sulfur-clus-
ter assembly protein implicated in a human disease, along
with frataxin and glutaredoxin 5. The interaction of
frataxin with ISCU and the biochemical and histological
features associated with this ISCU mutation also indicate
that themyopathy is caused by defects in iron-sulfur cluster
assembly and intracellular iron metabolism similar to Frie-
dreich ataxia, but with different tissue speciﬁcity. It has
been recently suggested that the downregulation of ISCU
in frataxin-deﬁcient cells further aggravates the deﬁciency
of iron-sulfur proteins in Friedreich ataxia.24,25 The novel
implication of ISCU in a human disorder may therefore
contribute to a better understanding of the role of frataxin
in mammalian iron-sulfur cluster assembly.
In addition, this myopathy with succinate dehydroge-
nase and aconitase deﬁciency is an interesting example
of a mutation that strengthens a weak splice acceptor
site, resulting in exon retention and the subsequent over-
expression of a deleterious isoform. Only a few examples
of this mutational mechanism have been reported previ-
ously.26,27 Alternative splice variants with aberrant exon
inclusion may also cause tissue-speciﬁc pathology due to
the tissue-speciﬁc expression of partner proteins.28 The
identiﬁcation of the disease-causing mutation in this met-
abolic muscle disease may offer new therapeutic options
for the affected patients, for example through modulation
of intracellular iron metabolism29 or correction of the
aberrant splicing with antisense oligonucleotides.30
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